Guaifenesin | CAS#93-14-1

MedKoo Cat#: 317981 | Name: Guaifenesin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Guaifenesin is an expectorant reported to have muscle relaxant and sedative activity. It is used in many cough preparations.

Chemical Structure

Guaifenesin

CAS#93-14-1

Theoretical Analysis

MedKoo Cat#: 317981

Name: Guaifenesin

CAS#: 93-14-1

Chemical Formula: C10H14O4

Exact Mass: 198.0892

Molecular Weight: 198.22

Elemental Analysis: C, 60.59; H, 7.12; O, 32.29

Price and Availability

Size	Price	Availability	Quantity
10g	USD 250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Guaifenesin; Guaiphenesin; Guaiacol glyceryl ether; Glycerol guaiacolate; Methphenoxydiol; Scott Tussin; Scott-Tussin; ScottTussin;

IUPAC/Chemical Name

3-(2-methoxyphenoxy)propane-1,2-diol

InChi Key

HSRJKNPTNIJEKV-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3

SMILES Code

COC1=CC=CC=C1OCC(CO)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Guaifenesin (Guaiacol glyceryl ether), a constituent of guaiac resin from the wood of Guajacum officinale Linné, is an expectorant.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	151.35
	DMSO	56.7	285.88
	Ethanol	27.5	138.74
	PBS (pH 7.2)	5.0	25.22

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 198.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Melegari C, Bertoni S, Genovesi A, Hughes K, Rajabi-Siahboomi AR, Passerini N, Albertini B. Ethylcellulose film coating of guaifenesin-loaded pellets: A comprehensive evaluation of the manufacturing process to prevent drug migration. Eur J Pharm Biopharm. 2016 Mar;100:15-26. doi: 10.1016/j.ejpb.2015.12.001. Epub 2015 Dec 11. PubMed PMID: 26686647. 2: Mahmoud WH, Mahmoud NF, Mohamed GG, El-Sonbati AZ, El-Bindary AA. Ternary metal complexes of guaifenesin drug: Synthesis, spectroscopic characterization and in vitro anticancer activity of the metal complexes. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Nov 5;150:451-60. doi: 10.1016/j.saa.2015.05.066. Epub 2015 May 29. PubMed PMID: 26067934. 3: Knych HK, Stanley SD, Benson D, Arthur RM. Pharmacokinetics of guaifenesin following administration of multiple doses to exercised Thoroughbred horses. J Vet Pharmacol Ther. 2016 Jan 14. doi: 10.1111/jvp.12287. [Epub ahead of print] PubMed PMID: 26763117. 4: Yehia AM, Mohamed HM. Chemometrics resolution and quantification power evaluation: Application on pharmaceutical quaternary mixture of Paracetamol, Guaifenesin, Phenylephrine and p-aminophenol. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:491-500. doi: 10.1016/j.saa.2015.07.101. Epub 2015 Jul 29. PubMed PMID: 26254602. 5: Thompson GA, Solomon G, Albrecht HH, Reitberg DP, Guenin E. Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. J Clin Pharmacol. 2015 Dec 3. doi: 10.1002/jcph.682. [Epub ahead of print] PubMed PMID: 26632082. 6: Maher HM, Alshehri MM, Al-taweel SM. Derivative emission spectrofluorimetry for the simultaneous determination of guaifenesin and phenylephrine hydrochloride in pharmaceutical tablets. Luminescence. 2015 May;30(3):330-6. doi: 10.1002/bio.2735. Epub 2014 Jul 10. PubMed PMID: 25044215. 7: Karrasch NM, Hubbell JA, Aarnes TK, Bednarski RM, Lerche P. Comparison of cardiorespiratory variables in dorsally recumbent horses anesthetized with guaifenesin-ketamine-xylazine spontaneously breathing 50% or maximal oxygen concentrations. Can Vet J. 2015 Apr;56(4):387-92. PubMed PMID: 25829559; PubMed Central PMCID: PMC4357912. 8: McIntyre IM, Navarrete A, Mena O. Postmortem distribution of guaifenesin concentrations reveals a lack of potential for redistribution. Forensic Sci Int. 2014 Oct 24;245C:87-91. doi: 10.1016/j.forsciint.2014.10.029. [Epub ahead of print] PubMed PMID: 25447180. 9: Molinaro Coelho CM, Duque Moreno JC, Goulart Dda S, Caetano LB, Soares LK, Coutinho GH, Alves GE, da Silva LA. Evaluation of cardiorespiratory and biochemical effects of ketamine-propofol and guaifenesin-ketamine-xylazine anesthesia in donkeys (Equus asinus). Vet Anaesth Analg. 2014 Nov;41(6):602-12. doi: 10.1111/vaa.12130. Epub 2014 Jun 25. PubMed PMID: 24961870. 10: Fayzullin RR, Lorenz H, Bredikhina ZA, Bredikhin AA, Seidel-Morgenstern A. Solubility and some crystallization properties of conglomerate forming chiral drug guaifenesin in water. J Pharm Sci. 2014 Oct;103(10):3176-82. doi: 10.1002/jps.24104. Epub 2014 Aug 4. PubMed PMID: 25091705. 11: Gong R, Lin X, Li P, Yu J, Rodrigues AE. Experiment and modeling for the separation of guaifenesin enantiomers using simulated moving bed and Varicol units. J Chromatogr A. 2014 Oct 10;1363:242-9. doi: 10.1016/j.chroma.2014.06.098. Epub 2014 Jul 7. PubMed PMID: 25047823. 12: Maher HM, Al-Taweel SM, Alshehri MM, Alzoman NZ. Novel stereoselective high-performance liquid chromatographic method for simultaneous determination of guaifenesin and ketorolac enantiomers in human plasma. Chirality. 2014 Oct;26(10):629-39. doi: 10.1002/chir.22354. Epub 2014 Jul 8. PubMed PMID: 25043279. 13: O'Connell OJ. Is extended-release guaifenesin no better than a placebo? Respir Care. 2014 May;59(5):788-9. doi: 10.4187/respcare.03319. PubMed PMID: 24789023. 14: Small E, Sandefur BJ. Acute renal failure after ingestion of guaifenesin and dextromethorphan. J Emerg Med. 2014 Jul;47(1):26-9. doi: 10.1016/j.jemermed.2014.01.022. Epub 2014 Mar 14. PubMed PMID: 24630853. 15: Janin A, Monnet J. Bioavailability of paracetamol, phenylephrine hydrochloride and guaifenesin in a fixed-combination syrup versus an oral reference product. J Int Med Res. 2014 Apr;42(2):347-59. doi: 10.1177/0300060513503762. Epub 2014 Feb 19. PubMed PMID: 24553480. 16: Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections. Respir Care. 2014 May;59(5):631-6. doi: 10.4187/respcare.02640. Epub 2013 Sep 3. PubMed PMID: 24003241. 17: Rumpler MJ, Colahan P, Sams RA. The pharmacokinetics of methocarbamol and guaifenesin after single intravenous and multiple-dose oral administration of methocarbamol in the horse. J Vet Pharmacol Ther. 2014 Feb;37(1):25-34. doi: 10.1111/jvp.12068. Epub 2013 Jul 17. PubMed PMID: 23859819. 18: Furcha R, Monnet J. Clinical assessment of the warming sensation accompanying flavor 316282 in a cold and cough syrup containing paracetamol, phenylephrine hydrochloride, and guaifenesin. SAGE Open Med. 2014 Jan 28;2:2050312113518198. doi: 10.1177/2050312113518198. eCollection 2014. PubMed PMID: 26770699; PubMed Central PMCID: PMC4607193. 19: Cockerill PA, de Cógáin MR, Krambeck AE. Acute bilateral ureteral obstruction secondary to guaifenesin toxicity. Can J Urol. 2013 Oct;20(5):6971-3. PubMed PMID: 24128843. 20: Duman O, Tunç S, Kancı Bozoğlan B. Characterization of the binding of metoprolol tartrate and guaifenesin drugs to human serum albumin and human hemoglobin proteins by fluorescence and circular dichroism spectroscopy. J Fluoresc. 2013 Jul;23(4):659-69. doi: 10.1007/s10895-013-1177-y. Epub 2013 Mar 8. PubMed PMID: 23471625.